Amneal Launches AG for Novo Nordisk’s ACTIVELLA® / by TI

Bridgewater, New Jersey (USA), November 20, 2014 – Amneal Pharmaceuticals LLC ( today announced the launch of Lopreeza™ (estradiol/norethindrone acetate) tablets in 0.5 mg/0.1 mg and 1 mg/0.5 mg strengths. Amneal’s product is the first Authorized Generic of the brand, Activella®, containing the identical formulation of estradiol/norethindrone acetate.

“With an Authorized Generic like Lopreeza™, pharmacists are able to provide their patients with the same brand products at a lower cost,” states Amneal Co-CEO Chirag Patel. “Consistency is critical in this therapeutic category. Women currently taking Activella® can now enjoy continuity of therapy by remaining on the brand product while benefiting from the generic savings.”
Both strengths of Lopreeza™ are now shipping. The tablets are sold in 28-count dialpack dispensers and available through wholesalers, distributors and directly to the trade.
Annual U.S. sales of estradiol/norethindrone acetate tablets were $116 million as of August 2014, according to IMS Health.
Visit for full prescribing information.